OA12738A - Pharmaceutical combinations of adenosine A-2A and beta-2-adrenergic receptor agonists. - Google Patents

Pharmaceutical combinations of adenosine A-2A and beta-2-adrenergic receptor agonists. Download PDF

Info

Publication number
OA12738A
OA12738A OA1200400164A OA1200400164A OA12738A OA 12738 A OA12738 A OA 12738A OA 1200400164 A OA1200400164 A OA 1200400164A OA 1200400164 A OA1200400164 A OA 1200400164A OA 12738 A OA12738 A OA 12738A
Authority
OA
OAPI
Prior art keywords
alkyl
crc6
adenosine
cycloalkyl
adrenergic
Prior art date
Application number
OA1200400164A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA12738A publication Critical patent/OA12738A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
OA1200400164A 2001-12-06 2002-11-28 Pharmaceutical combinations of adenosine A-2A and beta-2-adrenergic receptor agonists. OA12738A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129270.5A GB0129270D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
OA12738A true OA12738A (en) 2006-06-29

Family

ID=9927164

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400164A OA12738A (en) 2001-12-06 2002-11-28 Pharmaceutical combinations of adenosine A-2A and beta-2-adrenergic receptor agonists.

Country Status (37)

Country Link
EP (1) EP1455799B1 (fr)
JP (1) JP2005513041A (fr)
KR (1) KR100685557B1 (fr)
CN (1) CN1856314A (fr)
AP (2) AP2004003053A0 (fr)
AR (1) AR037634A1 (fr)
AT (1) ATE293982T1 (fr)
AU (1) AU2002351066B2 (fr)
BR (1) BR0214998A (fr)
CA (1) CA2469085A1 (fr)
CO (1) CO5580752A2 (fr)
DE (1) DE60203934T2 (fr)
DK (1) DK1455799T3 (fr)
EA (1) EA200400639A1 (fr)
EC (1) ECSP045132A (fr)
ES (1) ES2239728T3 (fr)
GB (1) GB0129270D0 (fr)
GT (1) GT200200258A (fr)
HN (1) HN2002000348A (fr)
HR (1) HRP20040517A2 (fr)
HU (1) HUP0402540A3 (fr)
IS (1) IS7280A (fr)
MA (1) MA27150A1 (fr)
MX (1) MXPA04005506A (fr)
NO (1) NO20042839L (fr)
NZ (1) NZ533054A (fr)
OA (1) OA12738A (fr)
PA (1) PA8560701A1 (fr)
PE (1) PE20030834A1 (fr)
PL (1) PL370739A1 (fr)
PT (1) PT1455799E (fr)
SV (1) SV2004001426A (fr)
TN (1) TNSN04101A1 (fr)
TW (1) TWI256388B (fr)
UY (1) UY27566A1 (fr)
WO (1) WO2003047598A1 (fr)
ZA (1) ZA200403966B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785969B1 (ko) * 2004-05-12 2007-12-14 동아제약주식회사 Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2022050230A1 (fr) * 2020-09-03 2022-03-10 学校法人埼玉医科大学 Composition inhibant l'activation d'un récepteur de l'adénosine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
SV2004001426A (es) 2004-05-07
HRP20040517A2 (en) 2004-10-31
DE60203934D1 (de) 2005-06-02
AU2002351066A1 (en) 2003-06-17
EP1455799A1 (fr) 2004-09-15
UY27566A1 (es) 2003-07-31
TWI256388B (en) 2006-06-11
JP2005513041A (ja) 2005-05-12
GT200200258A (es) 2003-08-22
KR100685557B1 (ko) 2007-02-22
PA8560701A1 (es) 2004-05-07
GB0129270D0 (en) 2002-01-23
IS7280A (is) 2004-05-21
HN2002000348A (es) 2005-02-04
AP2004003082A0 (en) 2004-09-30
PL370739A1 (en) 2005-05-30
DK1455799T3 (da) 2005-06-27
HUP0402540A3 (en) 2008-04-28
DE60203934T2 (de) 2006-02-23
PT1455799E (pt) 2005-08-31
WO2003047598A1 (fr) 2003-06-12
EP1455799B1 (fr) 2005-04-27
TW200300759A (en) 2003-06-16
CA2469085A1 (fr) 2003-06-12
HUP0402540A2 (hu) 2005-07-28
ES2239728T3 (es) 2005-10-01
AU2002351066B2 (en) 2007-10-18
EA200400639A1 (ru) 2004-12-30
CO5580752A2 (es) 2005-11-30
KR20050044697A (ko) 2005-05-12
MXPA04005506A (es) 2004-12-10
MA27150A1 (fr) 2005-01-03
BR0214998A (pt) 2004-12-28
AR037634A1 (es) 2004-11-17
AP2004003053A0 (en) 2004-06-30
TNSN04101A1 (fr) 2006-06-01
NO20042839L (no) 2004-07-05
CN1856314A (zh) 2006-11-01
PE20030834A1 (es) 2003-10-08
ZA200403966B (en) 2005-06-22
NZ533054A (en) 2007-02-23
ECSP045132A (es) 2004-07-23
ATE293982T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
OA12609A (en) An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
US7107985B2 (en) Pharmaceutical combination
US20040147544A1 (en) Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
OA12738A (en) Pharmaceutical combinations of adenosine A-2A and beta-2-adrenergic receptor agonists.
US20030109485A1 (en) Pharmaceutical combination
OA12736A (en) Combination of a selective PDE4 inhibitor and an adrenergic beta-2 receptor agonist.
AU2002316924A1 (en) An adenosine A2A receptor agonist and an anticholiergic agent in combination for treating obstructive airways diseases
AU2002344167A1 (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ZA200308602B (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.